Fulgent Genetics price target lowered to $35 from $40 at Piper Sandler

Piper Sandler lowered the firm’s price target on Fulgent Genetics to $35 from $40 and keeps a Neutral rating on the shares. The analyst updated estimates post the company’s earnings.